But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk A/S (NVO ... This price cut came just days after Eli Lilly reduced the price of its weight-loss drug Zepbound by at least $50 per vial. NVO stock gained nearly 4% on Wednesday.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading ... Learn More » That morning, Wegovy maker Novo Nordisk announced the latest clinical trial results for an advanced obesity drug ...

Like many pharma stocks, Eli Lilly ... drugs from Novo Nordisk, dominate the market. All of this has helped Lilly's revenue climb in the double digits in recent quarters and the stock price ...

Both of these products quickly became blockbusters and, along with drugs from Novo Nordisk ... or is Lilly stock still a buy? Let's find out. So, first let's talk about the Eli Lilly story ...